FIELD: biology.
SUBSTANCE: present invention relates mainly to molecular biology and medicine. In particular, the invention relates to a combined therapy of pathological conditions, such as cancer.
EFFECT: method of treating cancer involves introduction of therapeutically effective amount of c-met antagonist and EGFR antagonist.
5 cl, 9 tbl, 9 ex, 25 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TUMOUR TREATMENT IN SUBJECT | 2006 |
|
RU2404193C2 |
| COMBINATION OF APO2L/TRAIL AND EGFR INHIBITOR FOR CANCER TREATMENT, METHOD IN VITRO OF APOPTOSIS INCREASE AND APPLICATION OF COMBINATION FOR OBTAINING MEDICATION FOR CANCER TREATMENT | 2006 |
|
RU2429006C2 |
| COMBINED PRODUCTS CONTAINING TYROSINE KINASE INHIBITORS AND THEIR USE | 2013 |
|
RU2660354C2 |
| NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING MALIGNANT GROWTH | 2011 |
|
RU2587619C2 |
| COMBINED THERAPY | 2015 |
|
RU2695230C2 |
| THERAPEUTIC, DIAGNOSTIC AND PROGNOSTIC METHODS FOR BLADDER CANCER | 2015 |
|
RU2739942C2 |
| HGF BETA-CHAIN VERSIONS | 2006 |
|
RU2403261C2 |
| CONJUGATES OF CMET ANTIBODY AND DRUG AND METHODS OF USING | 2017 |
|
RU2740996C2 |
| METHOD OF TREATING GEFITINIB-RESISTANT CANCER | 2006 |
|
RU2405566C9 |
| USE OF THIOCHROMENO[2,3-C]QUINOLINE-12-ONE COMPOUND FOR TREATING NON-SMALL CELLS LUNG CANCER | 2016 |
|
RU2663929C2 |
